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Abstract 
 
Bone is one of the most dynamic tissues of the human body, characterized by its great ability 
to self-regenerate and self-remodel after injury. Bone tissue can be exposed to some 
diseases that compromise its self-renewal, such as osteomyelitis. 
Osteomyelitis is a bone infection that can be caused by many species of microorganisms, 
being Staphylococcus aureus (S. aureus) the most commonly isolated organism. Vancomycin 
is an important glycopeptide antibiotic known by its efficacy against S. aureus and thus, 
frequently used in cases of osteomyelitis. Although vancomycin is able to eradicate the 
bacteria, it has no ability to induce bone regeneration itself, so a combined treatment 
including a biomaterial which has the ability to induce tissue regeneration would be a good 
strategy.  
Nanohydroxyapatite/collagen (nanoHA/collagen) composites have been used for bone 
regeneration because of its similarity to bone, bioactivity, biodegrability and 
osteoconductivity and, thereforem, may stimulate bone regeneration. Taking advantage of 
these properties, nanoHA/collagen composites can be used as a controlled Drug Delivery 
System by associating them with heparin. Heparin is a linear polysaccharide produced in mast 
cells that can control the diffusion of vancomycin from the scaffold. 
The main purpose of this work was to assess bone cells behavior, namely osteoblasts and 
osteoclasts, cultured in contact with vancomycin continuously released from heparinized 
nanoHA/collagen granules. Based on different renewal kinetics, a sustainable release of 
antibiotic from the granules in PBS was confirmed and the amount of vancomycin released 
was enough to inhibit bacterial growth, remaining below MTC values for S. aureus. In both 
cell type tested, vancomycin did not reveal to be cytotoxic but instead it seemed to have 
cytostatic effect, according to TRAP and ALP activity assay performed. Nevertheless, TRAP 
and ALP activity results revealed that heparinized nanoHA/collagen granules mimetize bone 
tissue better than all other materials tested once cells were able to adhere, proliferate and 
differentiate even after being exposed to vancomycin effects. Therefore, heparinized 
nanoHA/collagen composite might be a good choice regarding osteomyelitis treatment as 
they are capable of inhibit pathogen growth, promote osseointegration and tissue 
regeneration.  
 
Keywords: Osteomyelitis, S. aureus, vancomycin, nanohydroxyapatite, collagen, heparin, 
osteoblasts, osteoclasts. 
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Resumo 
 
O osso é um dos tecidos mais dinâmicos do corpo humano, caracterizado pela sua 
capacidade regenerativa e de remodelação após lesão. O tecido ósseo pode ser alvo de 
doenças que o destroem e comprometem a sua auto-regeneração, como por exemplo a 
osteomielite. 
A osteomielite é uma infeção que afeta o tecido ósseo, tendo como principal causador da 
doença a bactéria Staphylococcus aureus (S. aureus). A vancomicina é um importante 
antibiótico pertencente à classe dos glicopéptidos, bem conhecido pela sua eficácia contra S. 
aureus e, portanto, frequentemente utilizado no tratamento da osteomielite.  
Compósitos de nanohidroxiapatite (nanoHA) e colagénio têm sido utilizados na regeneração 
óssea graças à sua semelhança com o osso, bioactividade, biodegradação e 
osteocondutividade. Tendo em conta essas propriedades, compósitos de nanoHA e 
colagénio podem ser utilizados como sistemas de libertação controlada, associados à 
heparina. A heparina é um polissacarídeo linear produzida pelos mastócitos e é utilizada, 
neste caso,  para controlar a difusão da vancomicina a partir do scaffold.  
O principal objetivo deste trabalho era avaliar o comportamento de células ósseas, 
nomeadamente osteoblastos e osteoclastos, em contacto com a vancomicina continuamente 
libertada a partir de grânulos de nanoHA e colagénio heparinizados. Baseando-se em 
diferentes cinétcas de renovação de fluidos, confirmou-se uma libertação controlada do 
fármaco dos granulos em PBS , e a quantidade libertada mostrou-se suficiente para inibir o 
crescimento bacteriano, permanecendo abaixo dos valores considerados tóxicos.  A 
vancomicina não revelou efeito citotóxico em nenhum dos tipos celulares testados. Ao invés 
disso, revelou um aparente efeito citostático. Apesar disso, os granulos heparinizados 
demonstraram mimetizar melhor o osso do que os restantes materiais testados, uma vez 
que as células revelaram uma melhor aderência, proliferação e diferenciação na presença 
desses grânulos. Portanto, grânulos de nanoHA/colagénio heparinizados poderão ser uma 
boa escolha no tratamento da osteomielite, uma vez que demonstraram ser capazes de inibir 
o crescimento bacteriano e, ao mesmo tempo, promover osseointegração e possível 
regeneração óssea.   
 
  
Palavras-chave: Osteomielite, S. aureus, vancomicina, nanohydroxyapatite, colagénio, 
heparina, osteoclastos, osteoblastos 
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Chapter 1: Introduction 
 
Bone is one of the most dynamic tissues of the human body, characterized by its high 
vascularization, rigidity, hardness and great ability to self-regenerate and self-remodel after 
injury without leaving a scar. (1-3)  This tissue is constantly in adaptation to preserve skeletal 
integrity and to regulate mineral homeostasis. 
Bone tissue serves a variety of functions from structural support for the rest of the body, 
which allows movement and locomotion, protection of vital internal organs such as lungs, 
brain and heart, maintenance of pH balance, to mineral reservoir for calcium, phosphorus 
growth factors and cytokines for balanced metabolism and also by providing a suitable 
environment for hematopoiesis in bone marrow. (4, 5) Therefore, due to all the functions 
described above, body balance can be considerably disturbed by any change in bone 
composition, structure or function.  
1.1.  Bone matrix composition  
Bone matrix is mainly constituted by two different components:  
- The inorganic component, consisting of calcium phosphate mineral apatite - essentially 
hydroxyapatite crystals (70 wt%) - which is responsible for bone hardness and rigidity, 
and a low percentage of ions. (3)  Crystalline hydroxyapatite [Ca 10 (PO4 )6(OH)2 ], with 
traces of other ions such as F-, Mn2+ Mg2+, CO32- and many others, is the main mineral 
component of bone, making up about a quarter of the volume of normal adult bone. (3)  
- The organic component, which is essentially composed by type I collagen (90% - 95%) 
and noncollagenous structural proteins, namely proteoglicans, sialoproteins and 
glicoproteins (osteopontin and osteocalcin). (3)   
 
Collagen forms fibrils of aligned protein helices (with 50 to 70 nm of diameter) where 
hydroxyapatite crystals (with 10 to 50 nanometer in length) are stuck. These crystals are 
sized and oriented according to collagen template, conferring a well- arranged nanoscale 
structure to bone. (6)   
This structure of bone is critical to reach its specific properties. So, the tissue can maintain a 
reasonable balance, i.e., nor extremely flexible (if the organic component would be removed) 
nor extremely hard and thus brittle (if the inorganic component would be removed).   
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1.2.  Bone architecture  
As shown in figure 1, bone’s organization is a highly hierarchical structure. (5)   
 
 
Figure 1. Bone microscopic composition. (7)  
 
Bone is usually classified as cortical (compact or dense) and/or trabecular (cancellous or 
spongy).(1, 4)  It is estimated that 80% of an adult human skeleton is composed by cortical 
bone and 20% is trabecular bone.(1, 5)   
 
Cortical bone is found mainly in the periphery of long bones, and in short and flat bones. It is 
dense and massive (only 10% porous) (1)  and surrounds the marrow space containing a 
great deal of blood vessels. (3, 5)   
Cortical bone also has an inner and an outer surfaces: periosteum and endosteum, 
respectively. The first one is a non-calcified connective tissue layer that covers the 
endosteum, except at joints. Periosteum is constituted by blood vessels, nerve fibers, 
osteoblasts and osteoclast, and it has important features in bone growth and fracture repairs 
once it protects, nourishes and supports bone formation. 
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On the other hand, endosteum is a membranous thin layer of connective tissue that covers 
the marrow cavities. This structure is responsible for bone growth and repair once it 
provides osteoprogenitor cell and osteoblasts.  
The periosteum is strongly connected to the outer cortical surface of bone by thick 
collagenous fibers, called Sharpeys’ fibers. (4)  
Cortical bone is also composed by units called osteons (or Haversian systems) which cannot 
be found in trabecular bone. Osteons are concentric cylinders of lamellae formed around 
the Haversian canal and they are considered the primary histological unit of bone. (4) In 
turn, each Haversian canal holds a blood vessel which supplies nourishment to the bone 
cells. (8)  Osteons can communicate with each other through Volkmann’s canals that are 
vascular spaces disposed obliquely or perpendicularly to them. (9)  
Trabecular bone is found within cortical bone, in medullary spaces and in the interior of 
short bones. It is composed of a set of polygonal network of trabecular plates and sticks 
highly interconnected, giving this type of bone a spongy-like appearance. (4, 5)  Unlike 
cortical bone, trabecular bone presents 50–90% of porosity, as seen in figure 2. (1)   
 
 
Figure 2. The two basic types of bone, trabecular and cortical bone. (10)   
 
Mineralized bone could be either woven bone (immature) or lamellar bone (mature). Woven 
bone is characterized by a random organization of collagen fibers, i.e., collagen fibrils are laid 
down in a disorganized way while lamellar bone is characterized by a parallel orientation of 
collagen into sheets, which confers to bone its significant mechanical strength. (3, 9)   
Bone marrow, in turn, is divided in two different parts: yellow bone marrow (composed 
essentially of fat) and red bone marrow (also known as myeloid tissue). It has as main 
functions the formation of blood cells, the removal of particulate matter from the blood and 
possible production of antibodies and plasma proteins. (11)  
4 
1.3.  Bone Cells  
Four characteristic cell types can be found within the bone homogeneous intercellular 
material: osteoblasts, osteocytes, osteoclasts and undifferentiated bone mesenchymal stem 
cells. (9) Each one has specific tasks that together are crucial for the maintenance of a 
healthy bone tissue. (1)   
1.3.1.  Osteoblasts and Osteocytes 
Found at the bone surface, where they form a tight layer of cells, osteoblasts, as well as 
adipocytes, chondrocytes, myoblasts and fibroblasts, are originated from multipotent 
mesenchymal stem cells that have the ability to differentiate into these cells when properly 
stimulated (Figure 3). They are polarized and present a cuboidal shape. (1, 12)   
Osteoblasts are responsible for the synthesis and regulation of new bone extracellular 
matrix constituents, being their major product the type I collagen and bone apatite. (1, 3, 12)  
Therefore, active mature osteoblasts present large nuclei, enlarged Golgi systems and 
extensive endoplasmic reticula. (4) They also express on their membrane surface a 
glycosylated protein called alkaline phosphatase (ALP). High levels of this protein are found 
in the blood during bone formation.  
Some of these cells are differentiated into osteocytes just before the end of the matrix 
secreting period, being entrapped in the new bone matrix, while the remained non-
differentiated cells are kept at the bone surface. Osteocytes are located in a cavities called 
lacuna and communicate with each other through canaliculi. (9)    
Osteocytes present a stellate shape and have less organelles than osteoblasts.  Their main 
function is to support bone structure and metabolism but also take part in the calcification 
of the osteoid matrix and in the blood-calcium homeostasis. (1, 3)  
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Figure 3. Origin and fate of osteoblasts. (13)   
1.3.2.  Osteoclasts  
Osteoclasts are terminally differentiated myeloid cells with specific characteristics to remove 
mineralized bone matrix by direct chemical and enzymatical attack. (9) They are the only 
cells known to be able to resorb bone. (4) Generally, these cells have a typically large 
multinucleated shape, containing a high number of mitochondria and expressing TRAP 
(tartrate-resistant acid phosphatase), which is associated with their activation and 
differentiation, and the calcitonin receptor. (2, 14)  
Two cytokines are considered critical for osteoclast formation: RANKL (Receptor Activator 
of Nuclear kB Ligand) and macrophage CSF (M-CSF). RANKL interacts with its receptor 
RANK expressed by pre-osteoclasts and therefore, promotes pre-osteoclasts fusion and 
differentiation into osteoclasts. (4) This interaction can be inhibited by a member of the 
tumor necrosis factor (TNF) receptor family of molecules - the Osteoprotegerin (OPG). 
OPG is a soluble protein which is mainly produced by osteoblasts but also by other cells in 
bone marrow, and acts as decoy (antagonist) receptor for the osteoclast differentiation. (12, 
15) On the other hand, M-CSF plays an important role in proliferation, survival and 
differentiation of osteoclast precursors. (4)  
To perform its main function, osteoclasts secrete H+ ions to dissolve the mineral 
component of bone and cathepsin K enzyme to digest the proteinaceous matrix, which is 
mostly composed of type I collagen. (4)  
 
6 
1.4.  Bone remodeling process 
Bone remodeling is a very important, dynamic and active process of synthesis and 
destruction that living bone is constantly undergoing in order to allow primary bone 
substitution in infants (woven bone to lamellar bone), remove damaged bone and to ensure 
a correct calcium homeostasis. (9, 16)   
This process, shown is figure 4, is carried out by osteoclasts and osteoblasts, responsible for 
resorbing (or destroy) old bone and form new bone respectively, in four sequential phases: 
activation, resorption, reversal and formation. (4)   
 
Activation phase 
The first step of bone remodeling process starts with an initiating remodeling signal which 
can be any external mechanical strength on bone that causes damages to the bone or 
internal factors, such as hormones, that leads to bone cells response. (2)  
In this phase, mononuclear monocyte-macrophage osteoclast precursors are recruited from 
the circulation and activated. Endosteum, which contains the lining cells on its surface, is 
stimulated and multiple mononuclear cells form multinucleated pre-osteoclasts by fusion. (4)  
 
Resorption phase 
During resorption phase, osteoclasts secrete hydrogen ions into the resorbing compartment 
in order to locally decrease the pH in the compartment and dissolve the inorganic matrix 
(HA crystals). To digest the organic matrix, these cells also secrete TRAP, cathepsin K, 
matrix metalloproteinase 9, and gelatinase. (4)   
Osteoclast activity during this phase produces irregular cavities at the trabecular bone 
surface named Howship’s lacunae or cylindrical Haversian canals in cortical bone. (3)  
 
Reversal phase 
The reversal phase takes place when the osteoclasts have completed the previous phase. 
The events that occur in this phase are still unclear but it is presumed that additional 
collagen degradation, deposition of proteoglycans and release of growth factors to start next 
phase may occur. (13)   
 
Formation phase 
Finally, the cavity created by resorption is filled in with osteoblasts. These cells are 
responsible for deposition of a mineralizable matrix, after having differentiated from their 
mesenchymal precursors. When this task is complete, osteoblasts acquire a flattened shape 
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and then line on the bone surface, becoming osteocytes when trapped in bone or else 
proceed to apoptosis. (13)  
Normal bone remodeling, with the correct balance between osteoclastic and osteogenic 
functions, is a crucial process to maintain a constant bone mass. (16)  It is more active in 
trabecular bone than in cortical bone because the first one has much larger surface area/ 
volume ratio. (12)  
 
 
Figure 4. Bone remodeling process. (17)   
1.5.  Osteomyelitis  
Osteomyelitis is a bone infection characterized by severe local inflammation, usually with pus 
formation, accompanied by bone destruction. This kind of infection can be caused by many 
species of organisms, with Staphylococcus aureus being the most commonly isolated 
organism.  
Osteomyelitis is normally caused by a combination of local trauma and an acute infection in 
any other part of the body. Then, it can remain localized or it can spread through other 
parts of the bone such as bone marrow, cortex, periosteum and the surrounding soft tissue. 
(18)  This disease can also be caused by bacteremia, surgery or orthopedic implants and it 
occurs more frequently in patients with diabetes mellitus, vascular insufficiency, or 
immunosuppression. Many other clinical conditions can make it easier for the infection to 
occur, such as neuropathy, intravenous drug use, open fractures, hemodialysis, sickle cell 
disease, dental infections, urinary tract infections and catheter-related bloodstream infection. 
(9)   
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The patients normally experience symptoms like fever, irritability, fatigue, nausea, tenderness 
and swelling around the affected bone and lost range of motion. These symptoms are very 
similar in the different cases of osteomyelitis. (9, 19)  
Its management depends on many factors such as the organism involved, the specific affected 
bone, the type (acute or chronic), the spectrum of the disease (extensive or localized), 
vascular supply, nerve function and others. So it must be individualized. (20)  
According to Lew & Waldvogel, osteomyelitis can be classified as acute or chronic, 
hematogenous or contiguous, and with or without vascular compromise. (21)   
 
Acute Osteomyelitis 
Acute osteomyelitis is usually a blood-borne disease that affects mostly children and it takes 
over days or weeks to evolve. (18, 21) The main symptoms are focal bone pain accompanied 
by fever or malaise. (22)   
Normally, a patient with acute osteomyelitis experiences sudden pain with tenderness, heat, 
swelling, and restricted movement of the affected area. Tachycardia, sudden fever, nausea, 
and malaise are some of the systemic symptoms associated to this condition. (18)   
 
Chronic Osteomyelitis 
Chronic osteomyelitis is a rare long-standing infection defined by clinical signs that persist 
for months or even years, with development of necrotic bone. It is a relapse of an acute 
osteomyelitis in the same area and generally accompanied by fever. (18, 21)  
Usually, chronic and acute osteomyelitis share the same clinical features, except that  
chronic osteomyelitis can persist for years. (18)  It is characterized by necrotic bone (called 
sequestrum), new bone formation and the presence of characteristic cells of an 
infection/inflammation such as leukocytes, lymphocytes, and histiocytes. (9)   
 
Hematogenous Osteomyelitis 
Hematogenous osteomyelitis is characterized by the direct seeding of the bone from 
bacteria present in the bloodstream. (23)   
This type of infection affects predominantly children and elderly because the metaphyseal 
regions of the long bones are much vascularized and more vulnerable to minor trauma. (24)  
In adults, it is more commonly caused by a secondary infection where the causing bacteria 
migrates by entering bloodstream and reaching the distal bone and marrow sites. Sometimes 
it is caused by the reactivation of an old focus developed previously. The most common 
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clinical features are fever, lethargy, tenderness and decrease of mobility of the injured area.  
(23)   
 
Contiguous Osteomyelitis 
Contiguous osteomyelitis normally appears after a trauma and nosocomial contamination 
acquired during surgical procedures. It can be considered as a secondary osteomyelitis once 
the infection originates from adjacent sources. (23, 25)   
1.5.1.  Epidemiology  
Due to an increase of cases of trauma, namely the ones caused by motor vehicles accidents, 
and orthopedic surgical procedures, there has been a high incidence of osteomyelitis caused 
by direct inoculation or contiguous focus of infection.  
In numbers, there are 3 to 25 % of cases of the infection that are secondary to open 
fractures; 15% of patients with foot ulcers caused by diabetes mellitus develop osteomyelitis 
and 36 % of the patients with diabetes tent to have recurrent infection. Vertebral 
osteomyelitis occurs in 2 % to 4 % of the patients and, in these cases, men are more 
frequently affected. (9)  
1.5.2.  Mechanisms of disease  
The affected area normally shows purulent inflammation where the bacteria are embedded.  
The destruction of bone trabeculae and bone matrix is stimulated by the inflammatory 
factors and leucocytes derived from all the inflammation process. This inflammation process 
is also responsible for the vascular channels compression, causing ischemia and consequent 
necrosis of the adjacent tissue. Due to this event, the antibiotics and inflammatory cells are 
not able to reach the affected area and the treatment of osteomyelitis may fail.  
Apparently, there is an increase of the osteoclast activity which causes a reactive hyperemia. 
The hyperemia is responsible for bone loss and localized osteoporosis. Once the growth 
factors and cytokines hormones are involved at the regulation of the bone cells (osteoclasts 
and osteoblasts) proliferation and activity, when their local concentration are altered, they 
also influence bone cells development and death. (21)  
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1.5.3.  Pathogenesis: Staphylococcus aureus 
Among the wide range of pathogenic microorganisms that can cause osteomyelitis, 
Staphylococcus aureus has proved to be the most virulent and it is the one implicated in 
most cases. (20, 21)  Despite the considerable amount of effective antibiotics for this type of 
microorganisms, Staphylococcus aureus presents a good versatility in escaping the treatment, 
becoming responsible for nosocomial and community-based infections, and also the major 
cause of morbidity and mortality. (20)  
S. aureus, shown in figure 5, is a gram-positive and non-motile coccus bacteria that grows by 
aerobic respiration or fermentation with diameters of 0.5-1.5μm and arranged like cluster of 
grapes. (26, 27)  The colonies present a gold pigmentation and positive results for coagulase 
tests. (28)  The cell wall of this bacteria is composed by a thick layer of peptidoglycan and 
teichoic acids, with adhesins and exotoxins attached. (26)  
  
Figure 5. SEM images of Staphylococcus aureus morphology (left) and staphylococcal biofilm covering a layer of 
bacteria. (26)  
 
In case of gram-positive bacteria, peptidoglycan constitutes over 50 percent of the cell wall’s 
weight. It is a polymer formed by a long polysaccharide chain composed by two sugar 
derivated subunits - N-acetylglucosamine (NAG) and N-acetylmuramic acid (29)  residues - 
alternated and linked by 1,4-β-linkages and many other amino acids (figure 6). Therefore, the 
peptidoglycan chains are cross-linked by tetrapeptide chains bound to NAM and by a 
pentaglycine bridge specific for S. aureus. (27, 28)  Three of the amino acids that compose 
this polymer (D-glutamic acid, D-alanine, and meso-diaminopimelic acid) cannot be found in 
proteins and their main function is to protect the bacteria against degradation by peptidases. 
Peptidases can only recognize the L-amino acid form. (27)  
Introduction 
 
 
   11 
 
 
Figure 6. (A) Schematic diagram of peptidoglycan structure. (B) Staphylococcus aureus peptidoglycan cross-
links:. NAM - N-acetylmuramic acid; NAG – N-acetylglucosamine; Gly – Glycine. Adapted from (27)   
Besides the main component of the gram-positive cell wall being a peptidoglycan, a fair 
amount of teichoic acids covalently bound to the polymer is also found. The teichoic acids 
are polymers of glycerol phosphate or ribitol phosphate attached by phosphate groups. 
When the teichoic acid is connected to the peptidoglycan by a covalent bond to plasma 
membrane lipids, they are called lipoteichoic acids. (27, 28)   Figure 7 shows the 
arrangement of these components. 
12 
 
Figure 7. A gram-positive cell wall components. (27)  
The real function of the teichoic acids remains unclear but they seem to extend the surface 
of the peptidoglycan and maintain the cell wall structure. They also seem to increase the 
negative charge of the cell wall, once they are negatively charged. (27)  
Staphylococcus aureus uses bacterial adhesins expressed on its surface (microbial surface 
components recognizing adhesive matrix molecules - MSCRAMM) to adhere to extracellular 
matrix proteins (such as fibrinogen, fibronectin, collagen, vitronectin, laminin, 
thrombospondin, bone sialoprotein, elastin, or von Willebrand factor) on host tissues. (30) 
This is an important factor in the early colonization of host tissues and implanted 
biomaterials because when S. aureus adheres to a surface by using the MSCRAMM, host cells 
cannot get rid of it. (21, 26, 31)  
S. aureus uses some factors, like protein A, toxins and capsular polysaccharides, to escape 
host defense mechanisms. It also uses exotoxins and degrading components of extracellular 
matrix (hydrolases) to invade and to penetrate the tissue (figure 8). All of the factors cited 
above show the ability of this bacteria to invade mammalian cells, colonize tissues and even 
persist after bacteremia. 
This bacteria can also survive within the epithelial or endothelial cells by promoting its 
endocytic uptake. This ability to survive inside the cells can explain the persistence of bone 
infection. (21) The biofilms that this bacteria forms increases the difficulty of the treatment 
with antimicrobial agents because biofilms are able to slow down the penetration of the 
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antimicrobial agents into the bacteria, protecting them from phagocytosis and antibiotics 
action. (21, 26)  
 
 
Figure 8. S. aureus structure and secreted proteins which are important virulence factors. (A) Surface and 
secreted proteins; (B, C) Cross-section of the cell envelope. (30)  
 
Staphylococcus aureus is a native colonizer of skin and nasopharynx but it can underline 
damaged tissue causing disease. The major problem is when the bacteria acquire resistance 
which is supported by the hospital environment, becoming hard to eradicate. (26)  
1.5.4.  Current Treatment 
In all cases of osteomyelitis should be considered a combined antimicrobial and surgical 
approach even though, in case of hematogenous osteomyelitis, the infection can be eradicate 
only by antibiotic treatment. The antimicrobial therapy requires observation and, if the 
infection persist after one week, surgery must be considered.  
A treatment including the administration of semisynthetic penicillin or vancomycin is the 
currently recommended treatment for osteomyelitis caused by Staphylococcus aureus 
although this treatment has some complications like a long stay at the hospital, which has 
high costs, and adverse events due to the use of intravenous catheters.  
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Surgery is absolutely necessary in cases where sequestra has already been formed, to 
remove the dead bone and surrounding soft tissue which act as foreign material. This 
procedure is delicate as the inadequate removal procedure of the infected parts is the major 
cause of recurrence in chronic osteomyelitis. (21) Even with appropriate medical and surgical 
treatment, about 20 % to 30 % of the patients has recurrence within 2 years. (9)   
This infection may have some complications including abscess formation, sepsis, bone 
deformity, limited range of movement, and motor and sensory deficits. (9)  
1.6.  Vancomycin 
Vancomycin is one of the most clinically important glycopeptide antibiotics because it is 
often considered the last line of defense against resistant pathogens, such as Staphylococcus 
aureus, that have developed resistance to penicillin, methicillin and other β-lactam 
antibiotics. (32)   
1.6.1.  Structure 
This antibiotic is a subclass of linear sugar from the vancomycin-ristocetin family, formed by 
peptides containing seven amino acids. (33)  Vancomycin’s carboxyl terminal is composed by 
a β-hydroxylated tyrosine, two phydroxyphenylglycine, a β-hydroxyty-rosine and a m,m`-
dihydroxyphenylglycine, and it also has aliphatic amino acids (generally leucine and 
asparagine), as shown in figure 9. (33)  
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Figure 9. Vancomycin structure (34)  
 
1.6.2.  Mode of action 
Some studies have shown that vancomycin’s mode of action includes the inhibition of 
peptidoglycan synthesis and, therefore, the bacteria cell wall synthesis. (33, 35)  
This antibiotic interacts with C-terminal D-Ala–D-Ala peptides of the lipid II, avoiding grow 
of the cell wall precursor by interfering with transglycosylase activity and possibly 
transpeptidase activity. Transglycosylase and transpeptidase activity are essential for 
synthesis of new cell wall and if these two are inhibited, a weak point in the new cell wall is 
created and bacteria become susceptible to lysis. (32, 36)  Vancomycin also alters the 
permeability of the cell membrane and RNA synthesis. (33)  
1.6.3.  Physicochemical properties 
Compared to other antibiotics, vancomycin has shown many advantages concerning 
physicochemical properties and cytotoxicity.  
Vancomycin presents an isoelectric point (pI) about 8.3 (37)  and it becomes cationically 
charged at physiological pH. The importance of being cationic lies in the interaction by 
charge-charge and hydrophobic interactions between the antibiotic and the membrane 
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bilayer of the bacteria (38) , i.e., being cationic improves the targeting of the antibiotic to the 
negatively charged bacterial cell membranes. (39)   
This antibiotic is considered an acidic antibiotic with a standardized low minimum inhibitory 
concentration (MIC) of 1µg/mL for S. aureus (40, 41) and is also considered one of the least 
cytotoxic antibiotics, an ideal point to contemplate when choosing antibiotics for bone 
application. (40, 41) Vancomycin has been documented as an effective antibiotic against 
Staphylococcus strains. (42)   
1.7.  Tissue regeneration: a new approach 
Nanohydroxyapatite (NanoHA) scaffolds, intended as a porous device, have been widely 
used as bone substitute to reduce the size of the hole created by necrosis. A scaffold can be 
permanent or temporary and offers mechanical support to adjacent tissue until the affected 
tissue naturally regenerates and remodels itself. Moreover, the characteristics of the material 
can be taken as advantageous to maximize tissue growth by adding some specific signaling 
molecules or even cells. (43)  
From bone infections perspective, having a local drug delivery system with a controlled and 
sustained release of antibiotic that could remain between the MIC and MTC values and, once 
the drug releasing is over, could still stimulate new bone formation and repair bone defects 
would be ideal for a successfully treatment. (42)  
Studies have shown that nanohydroxyapatite composites may be osteoconductive material 
and could stimulate bone regeneration. So, they have been indicated as an adequate bone 
substitute in the normal physiological environment. (44)   
Additionally, the referred biomaterial reveals an excellent release profile which is 
characterized by an initial rapid release of antibiotic and a long term sustained release to 
control infection over a longer period, according to some experiments. (42)  
Based on these studies, a biomaterial with the properties mentioned above which mimic 
bone composition was developed in order to treat bone infection and stimulate bone 
regeneration. Frequently, materials like hydroxyapatite and collagen are used for this 
purpose. 
1.7.1.  Hydroxyapatite  
Hydroxyapatite (HA, Ca10(PO4)6(OH)2) is a bioactive ceramic very similar in chemical 
composition and crystalline structure to natural HA crystals found in mineralized bone and 
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teeth (45, 46) which has been widely and successfully used for biomedical applications, 
including bone remodeling and matrices for drug release control. (47-49)  
This calcium phosphate-derived material has become increasingly used as a good candidate 
for orthopedic implants, artificial bones and scaffolds for tissue engineering owing to its 
positive biological response, the ability to adsorb various ions and organic molecules on its 
surface and also because of its interaction and strong affinity to host hard tissue. (45, 50)  
HA molecule features a hexagonal shape, as shown in figure 10, with a stoichiometric Ca/P 
ratio of 1.67 (47) , very similar to the Ca/P ratio found in natural bone. It is considered the 
most stable calcium phosphate ceramic compound in terms of thermodynamic properties 
when exposed to pH, temperature and composition of physiological fluid. (47)   
Patients with osteomyelitis usually presents bone defects with irregular shapes (21)  and it 
has been reported that one of the best way for of HA to be used in these cases are granules, 
besides this material can be molded into many shapes for clinical use such as powders, 
granules, porous blocks and films. (51)   
1.7.2.  Nanohydroxyapatite 
HA possesses an excellent bioactivity and biocompatibility however it reveals to have poor 
mechanical strength. (48, 52, 53)  
NanoHA (figure 10) is a new material that has taken advantage over HA and has been 
extensively studied in order to improve HA characteristics and therefore its performance as 
biomaterial for bone remodeling. NanoHA revealed a promising candidate to mimic bone 
tissue because of its nanometer dimensions compared to HA, which is more similar to the 
hierarchical structure of natural bone, and because of the large surface to volume ratio and 
higher surface reactivity it presents. (51)    
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Figure 10. Crystal structure of nanohydroxyapatite (5)  
 
Furthermore, NanoHA is even more similar to bone showing peculiar properties when 
compared to microsized HA (54)  regarding protein adsorption and bone cells adhesion, 
which can be controlled by varying pore and grain sizes as well as wettability. (55, 56)  It has 
been reported that these properties confer to the material the ability to enhance 
osteoblastic functions. (55)   
According to some studies, nanoHA also reveals a good potential as Drug Delivery System, 
(42)  so it can be used to treat chronic osteomyelitis by loading the material with antibiotic, 
namely vancomycin, due to its excellent mechanical and biological properties. (42, 57)  
1.7.3.  Collagen 
Collagen is a natural polymer and the main structural element of the extra cellular matrix 
(ECM) in many tissues, playing an important role on its integrity. (53, 58, 59)  It is 
synthetized by fibroblasts, (60) osteoblasts, chondrocytes and other cells. (60-62)   
There are over 20 different types of collagen. The main types of collagen identified in bone, 
cartilage, tendon, skin and muscle are type I, type II, type III, and type V, being type I collagen 
the most abundant in bone tissues where it serves as support to the nanosized 
hydroxyapatite crystals,(58) with its nanofibrous structure containing fiber bundles in a 
diameter range between 50 to 500 nm. (59)  
Regarding collagen structure, collagen molecule is formed by three polypeptide chains (α-
chains) wound around each other, creating a triple-helical rod-like structure named 
tropocollagen. (60, 62)  
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About 1000 amino acid residues compose each α-chain and it is believed that the high 
content of glycine affects a helix formation because of the uncommon amino acid sequence 
of the chains, following the formula (Gly-X-Y)n, where X is a proline and Y is a 4-
hydroxyproline. So, collagen is considered a polypeptide of tripeptide units where every 
third amino acid is a glycine. (62) The three α-chains are linked together by hydrogen bonds 
between adjacent -CO and -NH groups, and also by covalent bonds, as seen in figure 11. 
(60)  
 
 
Figure 11. Chemical structure of collagen type I. (a) Primary amino-acid sequence. (b) Secondary left handed 
helix and tertiary right handed triple-helix structure. (c) Staggered quaternary structure (63)  
 
Collagen has been more and more used in tissue engineering because of its good 
biodegradability and weak antigenicity compared to other natural polymers (53, 64)  and it 
also permits good cell attachment. (43) Moreover, depending on the desired mechanical 
properties for bone, fibril orientation of collagen can be changed by the degree of collagen 
crosslinking, which means that the polymer can be perfectly adapted to the purpose. (58)  
For many other reasons, such as good bioreabsorbability, non-toxicity, biocompatibility, 
compatibility with synthetic polymers, etc, (60)  this biological polymer added to a ceramic 
structure can offer many advantages when applied in bone regeneration. (65)   
Studies have shown that collagen may be a good choice as a component of a drug delivery 
system because it revealed a sustainable and adequate release of antibiotics. (60, 63)  
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1.7.4.  Combined hydroxyapatite and collagen material 
Natural bone composition and structure are some of the characteristics that must be taken 
in account when considering bone substitute material. (66)  
Creating a material similar to actual bone in composition, nanostructure and biological 
response is the main goal of bone substitutes (67) and composites combining hydroxyapatite 
and type I collagen material have shown great potential as biomaterial for bone substitution 
applications, once they closely mimic bone composition. (53, 66)  
Separately, these two material enhance osteoblast differentiation (68)  but studies have 
proved that when combined their properties are improved and tend to accelerate 
osteogenesis. (53) Additionally, the few reported cases concerning the mechanical properties 
of synthetic HA/collagen material and the toughness characteristics that it presents rend it a 
very promising material as bone substitute. (66)  
Some studies revealed that nanoHA/collagen material can be biodegraded by macrophages 
and the material presents good conditions which promotes bone cell attachment and 
proliferation. (66)  Therefore, nanoHA/collagen material is considered a promising system 
for bone remodeling (69)  because of its similarity to real bone, bioactivity and biodegrability. 
(66)  
1.7.5.  Heparin: Improving the combined hydroxyapatite and collagen 
material properties 
As referred above, creating a Drug Delivery System (DDS) with a controlled and sustained 
release of antibiotic would be ideal for the treatment of osteomyelitis. Associating heparin 
on biomaterials could be a good choice as heparin improves the performance of the 
biomaterial as drug carrier because of its advantageous biological activities helping to control 
the antibiotic release kinetics. (70)  
Heparin is a linear polysaccharide synthesized from a common precursor proteoglycan and 
produced in mast cells. (71)   
When it was first discovered, heparin was known as a blood coagulation inhibitor, i.e, with 
anticoagulant activity. But over time, heparin showed useful when used in delivery systems 
for different biomedical applications. This polysaccharide consists on repeating disaccharides 
units, mainly uronic acid and glucosamine residues (figure 12). (70, 71)  
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Figure 12. Heparin major and minor disaccharide sequences (70)  
 
Heparin (figure 13) has sulfate and carboxylate groups that give a high negative charge to the 
molecule. The extremely negative charge allows electrostatic interactions between heparin 
and many proteins which is a good reason to include heparin in the design of scaffolds for 
tissue regeneration and DDS with drug controlled release. (70, 72)  
 
 
 
Figure 13. Current conception of Heparin structure. (73)  
 
Studies have shown that heparin can be successfully conjugated to collagen during the 
crosslinking and thereby creating a composite that can be used both as bone regenerating 
tissue scaffold and as drug delivery system with a continuous release of molecules of 
interest, (72) namely vancomycin. The reported affinity of the delivery systems to specific 
small molecule and protein-based drugs used in biomedical applications is based on non-
covalent interaction to immobilize them in the scaffold and protect their biological activity 
and control the diffusion from the scaffold. (71)  
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Chapter 2: Materials and Methods 
2.1.  NanoHA granules 
A nanophased hydroxyapatite (nanoHA) slurry was impregnated to polyurethane (PU) 
sponges (Reticel Belgium) to produce scaffolds.  
To obtain the optimal consistence of the slurry, nanoHA powder (nanoXIM Hap202, 
Fluidinova S.A., Portugal), ultra-pure water and dispersive agent Dolapix CE64 (Zschimmer & 
Schwarz, Germany), were used in the ratio of 5 g : 4.4 mL : 200 µL respectively.  
After the impregnation, the sponges were let in the oven at 37 ºC for 30 minutes before 
being heat-treated in a sintering furnace (Thermolab). Afterwards, the scaffolds were let in 
the furnace until they were completely cooled.  
The sintered scaffolds were smashed and passed through sieves to obtain granules in a range 
size of 1.18 to 1.70 mm. (51)  
2.2.  Collagen addition to the nanoHA granules  
Type I collagen (Bovine Achilles tendon, Sigma-Aldrich) was dissolved overnight in HCl (0.01 
M, pH =2) at 4 ºC to prepare a 0.5 % (w/v) collagen solution, by using an Ultra Turrax (T25 
D, IKA®) at 10000 rpm. The solution was homogenized during 3 hours on ice. 
The 0.5 % collagen solution was diluted to a concentration of 0.05 % before it was applied to 
each granule. The nanoHA granules were distributed on petri dishes and collagen solution 
was added. Then, the granules were dried for 48 hours at room temperature (RT, 25 ºC), in 
a vacuum oven (Binder, Germany) to allow collagen to penetrate the granules.  
2.3.  Collagen crosslinking 
Since collagen-based matrices are not very durable without crosslinking, this procedure is 
carried on to stabilize and provide good mechanical properties to the material. (74)   
Therefore, collagen crosslinking was performed by using 57.5 mg of N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC, Aldrich) and 20.8 mg of N-
hydroxysuccinimide (NHS, Fluka) dissolved on 25 mL of 2-mofpholinoethane sulfonic acid 
(MES buffer, 0.05 M, pH=5.4, Sigma).  
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The samples were covered with the EDC/NHS crosslinking solution during 2 hours at 4 ºC. 
After the crosslinking reaction, the solution was removed and samples were washed 3 times 
with MES buffer. The samples were dried in a vacuum oven overnight. 
From several types of crosslinking procedures, the EDC/NHS crosslinking was chosen 
because of its non-cytotoxicity at low dosages. (74)  
2.4.  Collagen crosslinking with heparin immobilization  
Heparin immobilization was done at the same time as the collagen crosslinking was being 
performed. Therefore, heparin (Heparin sodium salt from porcine mucosa, Sigma) was 
dissolved in MES buffer (0.05 %, pH=5.4, Sigma) along with the EDC and NHS, in a ratio of 
188.3 mL MES : 0.433 g EDC : 0.157 g NHS : 3.766 g Heparin. The granules were distributed 
over a 24 wells plate, where the solution was added and left for 2 hours at 4 ºC. Once the 
reaction was completed, the crosslinking solution was removed and a phosphate buffer 
saline (PBS, pH=7.4) was added to the granules for 2 more hours to stop the heparin 
immobilization. 
Afterwards, the PBS was removed and a process of several washes was started with 2 M 
NaCl (during 4 hours), 4 M NaCl (6 hours) and ultra-pure water (8 hours).  Then, the 
granules were dried overnight in a vacuum oven at RT.  
2.5.  Loading nanoHA/collagen granules with vancomycin 
In order to adsorb vancomycin onto the nanoHA/collagen/Heparin granules, a 25 mg/mL 
(pH=4) concentrated solution of vancomycin was prepared and 1 mL of this solution was 
added to Eppendorf tubes with 20 mg of granules each. Then, the Eppendorf tubes 
containing the granules immersed in vancomycin solution were put in the orbital shaker (KS 
4000 IC, IKA®) at 37 ºC and 120 rpm for 24 hours.  
2.1.  Vancomycin release profile from heparinized nanoHA/collagen 
granules  
20 mg of nanoHA/collagen/Heparin/Vancomycin granules were transferred to polystyrene 
96-wells plate and 100 µL of fresh PBS (pH=7.4) were added in order to assess the 
vancomycin release profile. Granules were incubated in similar conditions of the performed 
cell culture, described in section “Osteoclast culture”. As negative control, granules with no 
added antibiotic were tested under the same experimental conditions. 
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Every 24 hours, 20 % of the content of the Eppendorf was collected for analysis and replaced 
by fresh PBS (Experiment A). In a parallel assay, in exactly the same conditions, all the 
content of the Eppendorf was withdrawn for analysis three times a week and replaced by 
fresh PBS (Experiment B). 
Experiment A, where 20 % of the PBS was replaced by fresh one every 24 hours, was first 
designed to simulate the normal extracellular fluid renewal of body.  Since this was not what 
would happen in cell cultures, Experiment B was designed to simulate the culture medium 
changing, ensuring that the vancomycin release profile was similar in both cases, although 
Experiment B does not correspond to actual extracellular fluid renewal. Experiment C was 
performed in similar conditions as experiment A and B but using a ratio of 20 mg/mL with 
full PBS replacement three times a week.  
Before the determination of vancomycin concentration on the supernatant, samples were 
centrifuged for 5 minutes at 14000 rpm to avoid the presence of particles in suspension. 
Vancomycin concentration was determined by using NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific) at 280 nm. 
To stablish a standard curve of vancomycin (figure 14), 5, 10, 15, 20, 25, 30, 40 and 50µg/mL 
of vancomycin solution samples were measured and the regression equation was calculated. 
Concentration and optical values are indicated in the X and Y axis, respectively, showing a 
linear correlation between these two values.   
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Figure 14. Standard curve of vancomycin 
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2.2.  Bioactivity assay with S. aureus 
Staphylococcus aureus (S. aureus) ATCC 25923 was first inoculated in a Nutrient Agar (NA, 
Liofilchem, Italy) and then a bacterial suspension on Tryptic Soy Broth (TSB, Difco, USA) 
was created. The bacterial suspension was adjusted to approximately 1.5 x 108 colony-
forming units per milliliter (CFU/mL). 
20 mg of nanoHA/collagen/heparin granules, previously loaded with vancomycin, were put in 
a glass tube with 1 mL bacterial suspension. TSB medium without bacteria and bacterial 
suspension without vancomycin were used as controls. 
The glass tubes were incubated in water bath gently shaken for 24 hours at 37 ºC. After 
incubation, absorbance was measured at 640 nm using a microplate reader (Spectramax 
M2e, Molecular Devices, Inc.). 
Samples were drawn every 24 hours and the absorbance values obtained from each one 
were converted to a total number of bacteria/mL based on a calibration curve. TSB medium 
was completely removed and replaced by fresh one. 
2.3.  Osteoclast culture 
Human peripheral blood mononuclear precursor cells (PBMNC) used in the osteoclast 
culture were isolated from blood of healthy donors, kindly provided by Instituto Português 
do Sangue (IPO, Porto).  
The blood was diluted with PBS (2 parts of PBS: 1 part blood) and then applied over Ficoll-
Paque (Sigma-Aldrich) to separate blood into its components. The mixture was centrifuged 
(400 x g, 10 minutes and room temperature). The cell layer on top of the Ficoll-Paque was 
collected, re-suspended in 45 mL of PBS and centrifuged once more under the same 
condition. Afterwards, supernatant was removed and cells were counted, re-suspended in 
culture medium and used immediately. (75)  
Cells were cultured on tissue culture polystyrene (TCPS) 96-wells plate with alpha Minimum 
Essential Medium (α-MEM, Gibco), supplemented with 30 % of serum from the donor, 10 % 
of M-CSF and RANKL growth factors, 1 % of penicillin-streptomycin (Gibco), fungizone 
(Gibco), sodium heparin (Sigma-Aldrich) and L-Glutamine (Sigma-Aldrich).  
20 mg of nanoHA/collagen/heparin granules, previously loaded with vancomycin, were placed 
in a TCPS 96-wells. NanoHA, nanoHA/collagen and nanoHA/collagen/Heparin (without 
vancomycin) granules were used as control. Samples were pre-incubated with α-MEM for 24 
hours, at 37 ºC and 120 rpm. Culture medium was changed three times a week. 
Materials and Methods 
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2.4.  Osteoblast culture  
MG63, a human osteoblast-like cell line derived from human osteosarcoma, were cultured 
on TCPS 96-wells plate with α-MEM (Gibco), supplemented with 1 % of penicillin-
streptomycin (Gibco), fungizone (Gibco) and ascorbic acid (Sigma-Aldrich) and 10 % of fetal 
bovine serum (FBS, Invitrogen). Cells were incubated in a humidified atmosphere of 95 % air 
and 5 % CO2. 
20 mg of nanoHA/collagen/heparin granules, previously loaded with vancomycin, were placed 
in a TCPS 96-wells. NanoHA, nanoHA/collagen and nanoHA/collagen/Heparin (without 
vancomycin) granules were used as control. Samples were pre-incubated with α-MEM for 24 
hours, at 37 ºC and 120 rpm. Culture medium was changed three times a week. 
2.5.  Tartrate-resistant acid phosphatase activity 
Tartrate-resistant acid phosphatase (TRAP) is an osteoclast enzyme marker that is involved 
in bone metabolism.   
Osteoclasts cultured on granules were washed with PBS and incubated 15 minutes with 0.1 
% Triton X-100, a cell lysis buffer. Afterwards, 80 µL of p-nitrophenyl phosphatase (p-NPP) 
substrate dissolved in 0.225 M sodium acetate, 0.3375 M KCl, 0.1 % Tx-100, 22.5 mM 
Sodium Tartrate, 0.225 mM iron chloride (pH = 5.8) were added and incubated at 37 ºC for 
1 hour. NaCl 5 M solution was added to stop the reaction and the absorbance was 
measured at 400 nm, using a SynergyMix, BioTek plate reader and Gen5 1.09 Data Analysis 
Software. The results of this test were normalized to total DNA content and expressed in 
nanomoles of p-nitrophenol produced per minute per microgram of protein (nmol min-1 µg 
protein-1). 
This test was performed at 7, 14 and 21 days of culture. 
2.6.  Alkaline phosphate activity  
To measure the alkaline phosphatase activity (ALP), cell cultured on granules were washed 
with PBS and incubated 15 minutes with 0.1 % Triton X-100. Then, 80 µL of p-nitrophenyl 
phosphatase (p-NPP) substrate dissolved in PBS were added and incubated at 37 ºC for 1 
hour. NaCl 5 M was added to stop the reaction and the absorbance was measured at 400 
nm using a SynergyMix, BioTek plate reader and Gen5 1.09 Data Analysis Software. The 
results of this test were normalized to total protein content and expressed in nanomoles of 
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p-nitrophenol produced per minute per microgram of protein (nmol min-1 µg protein-1). 
Total protein content was measured as described in the following section. 
ALP activity assay was performed at 7, 14 and 21 days of culture. 
2.7.  DNA and Protein content 
Cell proliferation was measured by DNA/Protein content of the cells on the material using 
PicoGreen® - dsDNA Quantitation Reagent, an ultra-sensitive fluorescent nucleic acid stain 
for quantitating double-stranded DNA (dsDNA). 
For that purpose, cells were washed twice with PBS and incubated for 15 minutes, at room 
temperature, with 100 µL 0.1 % Triton X-100. After incubation, 10 µL was transferred to a 
black TCPS 96-well plate with 90 µL of 1xTAE (Tris-acetate-EDTA) Buffer and 100 µL of 
PicoGreen® Reagent previously diluted in TAE Buffer were added to each well for 10 
minutes. 
This procedure had to be protected from light because PicoGreen® Reagent is susceptible to 
photodegradation. Fluorescence was determined on a SynergyMix, BioTek plate reader and 
Gen5 1.09 Data Analysis Software, with excitation at 485 nm and emission at 528 nm. This 
test was performed at 7, 14 and 21 days of culture. 
2.8.  Cell proliferation/viability 
Resazurin test 
Nontoxic Alamar blue dye (Resazurin) test was performed to measure the MG63 viability. 
Viable cells with active metabolism are able to reduce Resazurin to resofin, a fluorescent 
form of Alamar Blue and the amount of the reduced form produce is proportional to the 
number of viable cells. 100 µL of 10 % (v/v) Alamar blue dye solution in culture medium was 
added to each well and incubated at 37 ºC in a humidified atmosphere of 95 % air and 5 % 
CO2. After 3 hours of incubation, the solution was transferred to a black TCPS 96-well 
plate and fluorescence was monitored at 530 nm excitation wavelength and 590 nm emission 
wavelength in a SynergyMix, BioTek plate reader and Gen5 1.09 Data Analysis Software 
plate reader. This test was performed at 1, 7, 14 and 21 days of culture. (76)  
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2.9.  Cell morphology 
Scanning Electron Microscopy (SEM) 
Granules from 7, 14 and 21 days of culture were washed with pre-heated PBS and then fixed 
with a 1.5 % glutaraldehyde (v/v) solution in 0.14 M sodium cacodylate buffer at room 
temperature for 20 minutes. The granules were then washed twice with PBS and dehydrated 
with a growing ethanol (99%)/water gradient, maintaining them in 50, 60, 70, 80, 90 and 99% 
for 10 minutes each. 100 µL of hexamethyldisilazane (Sigma) was added to each well and the 
samples were dried overnight in the hood. 
The samples were mounted onto aluminum supports using AralditeTM, sputter coated with 
palladium-gold and then observed on SEM, using a High Resolution Scanning Electron 
Microscope with X-Ray Microanalysis with JEOL JSM 6301F/ Oxford INCA Energy 350 and 
Electron Backscattered Diffraction analysis with Quanta 400 FEG ESEM / EDAX Genesis 
X4M.  
 
Confocal Laser Scanning Microscopy (CLSM) 
Granules from 7, 14 and 21 days of culture were washed with pre-heated PBS and then fixed 
with a 3.7 % formaldehyde during 20 minutes. The samples were washed twice with PBS and 
0.1 % Triton X-100 was added for 5 minutes to permeabilize cells. Afterwards, 1 % Bovine 
Serum Albumin (BSA) was added to the samples and incubated at 37 ºC for 30 minutes. 
Alexa Fluor 594 Phalloidin (1:4000, Molecular Probes A12379, Invitrogen) fluorescent dye in 
1 % BSA was used to stain F-actin filaments for 30 minutes, at room temperature. Samples 
were washed with PBS and then, cell nuclei were stained with 4′ ,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI, Sigma-Aldrich) solution at RT for 10 minutes in the dark. Samples 
were washed with PBS twice more and Vectashield Mounting Media was added to prevent 
photobleaching.  
Granules were transferred to a proper support to obtain images with a Leica SP2 Confocal 
microscope, using a 10x water objective. 
2.10.  Statistical analysis 
For each condition, three replicas were tested and data are expressed as the mean ± 
standard deviation. Statistical differences were tested by one-way analysis of variance (One-
Way ANOVA), followed by the post hoc Tukey’s test for multiple comparisons (SPSS 20.0 
for windows, U.S.A).  Difference was considered statistically significant for values of p≤0.05. 
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GraphPad Software version 5.02 (GraphPad Software, Inc., U.S.A).was also used to perform 
data analysis. 
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Chapter 3: Results 
3.1.  Vancomycin release profile from heparinized nanoHA/collagen 
granules  
Figure 15 shows the vancomycin release profile from heparinized nanoHA/collagen granules 
during 360 hours, with 20 % (experiment A) of PBS substitution everyday and total 
substitution of PBS three times a week (experiment B).  
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Figure 15. Vancomycin release profile from heparinized nanoHA/collagen granules over time. Experiment A 
(ratio= 200 mg/mL), where 20 % of PBS solution was substituted in each time point and Experiment B (ratio= 
200 mg/mL), where complete substitution of PBS solution were performed in each time point.  
 
Considering Experiment A, where 20 % of PBS was replaced every 24h and Experiment B, 
where all PBS was replaced by fresh PBS three times a week, the pattern of release is similar 
but in Experiment B, the concentration of vancomycin released at each time point is 
significantly lower than in Experiment A. For both experiments, vancomycin concentration 
remained above MIC for S. aureus (1µg/mL), at least until 312 hours, and below MTC (50 
32 
µg/mL) for S. aureus, although the mass of granules used in these two experiments was 
higher than the amount used in Experiment C. 
 
Concerning Experiment C (figure 16), where all PBS was replaced by fresh one three times a 
week, the concentration of vancomycin released in each time point was similar compared to 
an experiment (77)  where 20% of PBS was replaced every 24h, using the same amount of 
granules. 
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Figure 16. Vancomycin release profile from heparinized nanoHA/collagen granules over time. Experiment C 
(ratio = 20 mg/mL), where PBS was completely substituted by fresh one three times a week.  
3.2.  Bioactivity assay with S. aureus 
Microbiology assays were performed with heparinized nanoHA/collagen granules, previously 
loaded with vancomycin in order to evaluate the amount of vancomycin being released and 
its capacity to inhibit S. aureus growth over time. 
The results (figure 17) showed an inhibition of S. aureus growth in all 4 replicates up to 192 
hours of antibiotic’s release. From 312 hours of release, all replicates exhibited bacterial 
growth. Table 1 shows S. aureus growth inhibition by vancomycin being released from 
heparinized nanoHA/granules over time. 
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Figure 17. S. aureus growth in the presence of granules loaded with vancomycin compared to control (granules 
without vancomycin) versus time. Statistically significant differences were evident between replicates with and 
without vancomycin. * represents statistically significant differences when compared to S. aureus bioactivity at 
0, 312, 336 and 360 hours. (p<0.05). 
 
 
Table 1. S. aureus growth inhibition for each timepoint of released vancomycin. (-) No growth; (++) Growth in 
2 replicates; (+++) Growth in 3 replicates; (++++) Growth in all replicates 
Time (h) 24 48 72 96 120 144 168 192 216 240 264 288 312 336 
S. aureus 
Growth 
- - - - - - - - - - ++ +++ ++++ ++++ 
 
3.3.  Osteoclast culture 
Tartrate-resistant Acid Phosphatase activity  
Tartrate-resistant acid phosphatase activity (TRAP) was measured to determine the 
osteoclast differentiation. As observed in figure 18, TRAP activity increased in all materials 
combination, except for the condition with vancomycin. 
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Figure 18. TRAP activity after 7, 14 and 21 days of osteoclasts cell culture with nanoHA, nanoHA/collagen, and 
nanoHA/collagen/Heparin granules (with and without vancomycin). TCPS was used as control and culture 
medium was changed once a week. * represents statistically significant differences when compared with the 
same material at 7 and 14 days of culture; ** represents statistically significant differences when compared to 
nanoHA granules at the same timepoint; + represents statistically significant differences when compared to 
granules without vancomycin and TCPS at the same timepoint. (p<0.05). 
 
It is clear that vancomycin inhibits osteoclastogenesis at 7 days of culture and cells were not 
able to restore their function, even after 14 and 21 days of culture when the release of 
antibiotic is lower.  
Comparing cell response to nanoHA/collagen and nanoHA/collagen/Heparin with TCPS 
(control), it is possible to see a significant osteoclast differentiation in the presence of the 
biomaterial after 21 days of culture. There were no statistical differences between 
osteoclasts cultured on nanoHA/collagen and nanoHA/collagen/Heparin. 
As the effects of vancomycin showed to be devastating for osteoclast cells when medium 
was changed once a week, a comparative study was performed to test the leaching power by 
changing the medium culture three times a week. Osteoclast behavior was independent of 
culture medium since no statistically significant differences were observed between cultures 
(figure 19). 
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Figure 19. TRAP activity after 7, 14 and 21 days of osteoclast culture with nanoHA, nanoHA/collagen, and 
nanoHA/collagen/Heparin granules (with and without vancomycin). TCPS was used as control. Culture medium 
was changed 3 times a week. . * represents statistically significant differences when compared with the same 
material at 7 and 14 days of culture; ** represents statistically significant differences when compared with 
nanoHA/collagen granules at the same timepoint; *** represents statistically significant differences when 
compared to nanoHA granules at the same timepoint; + represents statistically significant differences when 
compared to granules without vancomycin and TCPS at the same timepoint. (p<0.05). 
 
Cultures performed in the presence of heparinized nanoHA/collagen granules displayed 
significantly higher values of TRAP activity, when compared to cultures performed on other 
biomaterial combination at day 21. Cells cultured on heparinized material without 
vancomycin showed an increased cell differentiation from 14 to 21 days of culture.  
 
Cell morphology 
Osteoclast morphology on different materials combination, as previously described in 
“Materials and Methods”, was possible to be assessed by SEM (Figure 21). But only results 
for nanoHA/collagen/Heparin (with and without vancomycin) were found relevant.  
SEM images showed that cells adhered to the granules without vancomycin and were able to 
proliferate, acquiring elongated morphology at days 14 and 21. In the absence of vancomycin, 
there were no significant differences when comparing cells morphology on 
nanoHA/collagen/heparin and nanoHA or nanoHA/collagen granules, unlike the results 
shown for TRAP activity. 
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In the presence of vancomycin, round cells were observed until day 14 and at 21 days of 
culture. No cells were observed in any of the tested biomaterials.  
Results 
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Figure 20. SEM images of osteoclasts on nanoHA/collagen/Heparin (with and without vancomycin) 
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3.4.  Osteoblast culture 
Resazurin test 
Results of the Resazurin assay are represented in figure 21. These results show that 
metabolic activity of MG63 significantly decreased in the presence of vancomycin compared 
to TCPS. Vancomycin did not affect substantially cell proliferation in the first 24h but after 7 
days of culture, metabolic activity was significantly lower. 
At 21 days of culture, metabolic activity has increased in all tested materials when compared 
to the previous timepoint (14 days). No statistical differences were found between cells 
cultured with and without vancomycin, at 14 and 21 days of culture. 
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Figure 21. Proliferation of MG63 cells cultured on nanoHA, nanoHA/collagen, nanoHA/collagen/Heparin and 
nanoHA/collagen/Heparin/Vancomycin granules for 1, 7, 14 and 21 days, estimated by Resazurin assay. * 
represents statistically significant differences when compared with the same material at 14 days of culture; ** 
represents statistically significant differences when compared with nanoHA/collagen granules at the same 
timepoint, (p<0.05). 
 
 
Alkaline Phosphate Activity (ALP) 
Figure 22 shows that ALP activity diminished with culture time in all materials tested in the 
present study. 
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Excluding TCPS (control), the highest and more consistent values for ALP activity at 7, 14 
and 21 days of culture were observed for nanoHA/collagen/heparin material. These values 
were significantly higher when compared to MG63 cultured on nanoHA and on 
nanoHA/collagen/heparin/vancomycin but showed no statistically differences when compared 
to MG63 cultured on nanoHA/collagen granules. 
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Figure 22. ALP activity of MG63 culture on nanoHA/collagen/Heparin granules (20 mg/L), with and without 
vancomycin after 7, 14 and 21 days of culture. . * represents statistically significant differences when compared 
with the same material at 7 and 14 days of culture; ** represents statistically significant differences when 
compared with nanoHA, nanoHA/collagen and nanoHA/collagen/heparin/vancomycin granules at the same 
timepoint; + represents statistically significant differences when compared to granules without vancomycin and 
TCPS at the same timepoint. (p<0.05). 
 
MG63 cells were cultured under similar conditions but using a 100 mg/L ratio of granules 
instead of 200 mg/L. This preliminary study showed that the previously used ratio in 
osteoblast cultures might be inadequate for those cells growth (figure 23). 
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Figure 23. ALP activity of MG63 culture on nanoHA/collagen/Heparin granules (ratio = 100 mg/L), with and 
without vancomycin after 7, 14 and 21 days of culture. * represents statistically significant differences when 
compared with the same material at 7 and 14 days of culture; ** represents statistically significant differences 
when compared with the same material at 14 days of culture. (p<0.05).  
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Chapter 4: Discussion 
 
Osteomyelitis is a bone infection usually accompanied by bone necrosis which is stimulated 
by an inflammation process. This process is responsible for the vascular channels 
compression, causing ischemia and resulting in necrosis of the adjacent tissue. As a 
consequence, the antibiotics administered by oral or intravenous route may not be able to 
reach the affected area and the treatment of osteomyelitis might fail. (18, 21)  Hence, a local 
delivery of antibiotics from an implantable bone replacement material offers considerable 
advantages over these traditional methods. (41, 78)  
It has been reported that a local and sustained release system of antibiotic in the treatment 
of this infection is advantageous as it maintains a localized release of the drug in adequate 
amounts and a more effective control of bacterial growth. (79) The nanoHA/collagen 
composites used in this work were specifically designed as a controlled drug delivery system 
to carry an antibiotic intended to locally treat bone infection. In this case the chosen 
antibiotic to treat osteomyelitis was vancomycin as glycopeptides are known to be very 
effective antibiotics against gram-positive bacteria, namely S. aureus and methicillin-resistant 
Staphylococcus aureus (MRSA). (32, 80)  
Previously, these composites were studied and presented adequate dimensions (1.18-1.70 
mm) to fill bone defects including those caused by infections in humans and to perform in 
vivo studies in rat models. (77)  Granules with similar dimensions used for bone substitution 
were successfully used in clinical application and are already in the market. (81)   
Strength and macroporosity,  besides the micro and nanoporosity of these biomaterial were 
also ideal to be used in osteomyelitis cases,(77)  inducing bone-like apatite formation (82)  
and enhancing initial cell attachment (83) . The granules were characterized by ATR-FTIR 
and micro-CT, showing that the material had adequate porosity (62.7 ± 1.5 %) for bone 
regeneration. The average mean pore size obtained (227.3 ± 7.2 µm) is adequate for 
osteogenesis. The granules also presented adequate porosity for osteoblasts invasion and 
mobility to the most inner regions of the granules (77) once osteoblast average size is 20 – 
30 µm. (84)  
Concerning collagen concentration used in the granules, 0.05 % was considered the most 
suitable among all concentrations tested. The inclusion of collagen provides a better 
interaction between the material and molecules, bacteria and cells as it happens in bone. (77)  
These biomaterials are also designed to promote osseointegration and 
osteoconductivity.(85) It is expected that nanoHA/collagen composites favor the 
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proliferation and differentiation processes of bone cells and accelerate the damaged tissue 
healing process. Therefore, the study of vancomycin influence continuously released from 
heparinized nanoHA/collagen composites on osteoblasts and osteoclasts cells is of great 
interest for bone tissue regeneration. 
 
Considering the vancomycin release from granules, results showed that in experiment A the 
granules were able to release antibiotic in a sustainable way and enough to inhibit bacterial 
growth. The same was observed in experiment B and C. So, changing the medium (replacing 
20 % of the PBS every 24 hours and replacing all the PBS three times a week) seems not to 
have influenced the release profile of vancomycin.  
The results showed that even under extreme conditions, as observed in experiment B (total 
replacement of PBS), the controlled release profile of vancomycin was identical. So, based on 
results of this study, we can predict that under normal conditions the vancomycin release 
pattern from heparinized nanoHA/collagen granules should be similar. 
Although the release profile seems to be adequate, in vivo conditions might be altered 
namely the pH found in the infection site. Therefore, it must be taken in account that this 
release profile of vancomycin can be completely altered once that the local pH in the vicinity 
of infection site is different from the pH of PBS used to perform this study. (86) Vancomycin 
is slowly released in PBS because it becomes less positive when in contact with the buffer 
solution (77) and therefore the links stablished between the biomaterial and the antibiotic 
become weaker, allowing the latter releasing. Initially, rapid release of antibiotic in local site 
of infection might be favorable in order to prevent bacterial resistance. (87) Consequently, 
an initial burst of vancomycin release may be advantageous as observed in this study.  
 
Concerning the bioactivity studies of S. aureus, directly exposed to vancomycin released 
from heparinized nanoHA/collagen granules, the bacteria were not able to grow up to 192 
hours of antibiotic release, as shown in figure 17, which means that the amount of 
vancomycin being released remained above MIC. (41) These results were expected since 
vancomycin release profile in PBS assay showed a controlled antibiotic release over time, 
presenting values considered adequate to inhibit bacterial growth.  
A previous study (77) that used Broth microdilution method, showed that the released 
vancomycin was able to inhibit bacterial growth up to 216 hours and assumed that the 
dilution of released vancomycin concentration was responsible for the loss of capability to 
inhibit S. aureus growth.  
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In the clinical setting, a fluorescence polarization immunoassay (FPIA) is used to determine 
the concentration of vancomycin present in patient’s serum. FPIA measures tracer binding 
directly by using competitive-binding assay principles. (88)  The technique requires specific 
instrumentation to measure the polarized fluorescent light and the assay is generally more 
expensive. (89)  Therefore, as it was impossible to measure vancomycin concentration 
directly in patients’ serum with FPIA, the method used in the present study was a direct 
method to assess vancomycin release from the granules.  
Once the antibiotic is being directly released on the bacteria, the direct method used allows 
a better simulation of the vicinity of the infection, avoiding the limitations of the Broth 
Microdilution method described above. The evaluation of bacterial bioactivity indicated that 
heparinized nanoHA/collagen granules loaded with vancomycin should be able to eradicate 
the bacteria after a shorter period of treatment than the one presently used in clinical 
applications by intravenous administration of antibiotic, which is usually 4 to 6 weeks. (24, 
90, 91)  In some cases, it can be even extended up to 6 months. (91)  
By crossing data with the release profile of vancomycin from nanoHA/collagen in PBS assay 
(figure 24), the bacterial growth after 216 hours may be due to insufficient vancomycin 
release to inhibit S. aureus growth, i.e. the concentrations of vancomycin might be below S. 
aureus MIC (1 µg/mL), at this point.  
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Figure 24. S. aureus growth inhibition for each timepoint of released vancomycin. (-) No growth; (+++) 
Growth in 3 replicates; (++++) Growth in all replicates.  
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Osteomyelitis is well known by the damage it causes in bone, presenting general vascular 
insufficiency which leads to bone necrosis. Several studies suggest that a successful 
management of the infection requires a combination of target antibiotic therapy and surgical 
interventions, which implicates bone debridement to remove dead tissue. (23, 29, 86, 90)  It 
is important to take into account that the delivery system based on heparinized 
nanoHA/collagen granules loaded with vancomycin has as main purpose to eradicate the 
bacteria responsible for inducing osteomyelitis and, at the same time, to promote bone 
regeneration, by stimulating cells responsible for the bone remodeling process. 
Osteoblast-like MG63 and human osteoclasts cells cultures were performed to assess cells 
behavior in the presence of the antibiotic. The results from both cultures showed a 
substantial decrease of cells’ metabolic activity and differentiation over time when in contact 
with vancomycin. 
Regarding osteoclasts culture, vancomycin did not reveal to be cytotoxic but instead a 
cytostatic effect on cells seems to occur. Cells’ differentiation was low and presented a 
similar TRAP activity while cells cultured without vancomycin showed increased values over 
time. 
Initial studies, where the culture medium was changed once a week (Figure18), showed a 
marked TRAP activity decrease in cells exposed to vancomycin, suggesting a low cell 
differentiation and cells exposed to vancomycin were unable to recover activity. However, 
osteoclasts cultured without vancomycin, namely nanoHA/collagen and heparinized 
nanoHA/collagen granules, increased significantly TRAP expression when compared to 
nanoHA granules, indicating a higher cell differentiation at 21 days of culture. Data suggest 
that collagen plays an important role in bone cells behavior, enhancing cell adhesion as also 
shown by other authors. (92)  Studies suggested that collagen induces differentiation, (93) 
enhancing cells adhesion. (94) Since collagen is one of the main components of bone tissue, 
cells probably recognize the material as if it were real bone. 
A new culture was performed under similar conditions but changing the culture medium 
three times a week to exclude the possibility of medium saturation by the vancomycin being 
released from the granules. In accordance to the release profile observed in figure 16, during 
the first days of culture, vancomycin released from granules was considerably higher.  
The medium change does not seem to interfere in osteoclast differentiation since significant 
changes in TRAP activity were not observed. 
Although the results did not significantly differ from the ones obtained with the first cultures 
(figure 18), cells also showed a significantly improved behavior in terms of differentiation 
when in contact with heparinized nanoHA/collagen granules.  
Discussion 
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Heparin seems to stimulate osteoclasts activity. It was reported by Atsushi et al that this 
glycosaminoglycan enhances bone resorption in rat osteoclasts in vitro (95)  and Chowdhury 
et al also described an increase in osteoclast number in the presence of heparin. (96)  
Concerning osteoclasts activity, it is known that bone resorption can be inhibited by 
physiological regulators such as Osteoprotegerin (OPG), Nitric Oxide, interleukins 4 and 18, 
Transforming Growth Factor beta (TGF-β), interferon gamma and systemic hormones (PTH, 
calcitonin and prostaglandins). (97, 98)   
Some of these factors are secreted by osteoclasts, specially Nitric Oxide and TGF-β (99) (a 
potent inhibitor of osteoclastic bone resorption), (97)  in response to external factors. In 
this case, high levels of vancomycin released from the granules associated to the small 
amount of medium used in the culture (100 µL) would be the external factor that stimulates 
the secretion of osteoclastic inhibitor factors.  
In terms of MG63 osteoblast-like cells proliferation, it was possible to observe that 
metabolic activity decreased until day 14 in all tested materials and that heparinized 
nanoHA/collagen granules resulted in higher overall cell growth than nanoHA/collagen 
granules from 14 to 21 days of culture as nanoHA granules (figure 21).  
 
As well as in osteoclasts culture, vancomycin showed a negative effect on MG63 
differentiation (figure 22). 
Although ALP activity was significantly lower in the presence of vancomycin when compared 
to MG63 cultured on nanoHA/collagen or heparinized nanoHA/collagen granules, ALP 
activity was considerable increased from 14 to 21 days of culture, meaning that cells might 
be able to restore their normal activity as vancomycin release from granules diminished over 
time. This result proved the efficacy of the nanoHA/collagen composites in enhancing the 
osteoblastic phenotype expression level and also osteogenic traits, as it has been already 
reported by Shiao-Wen Tsai et al. (100)  
The comparison between the MG63 osteoblast-like cells culture using ratios of 100 mg/L  
and 200 mg/L granules showed that the 100 mg/L ratio performed better. More test must be 
carried out on the 200 mg/L as this ratio appears to be excessive for the available volume of 
culture medium inside the wells.  
These findings are supported by a study (77)  performed with of MC3T3-E1 cells on granules 
containing vancomycin and using a 100 mg/L ratio. C. Coelho (77)  observed that metabolic 
activity significantly increased even after being exposed to the antibiotic. 
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The literature (101)  also suggests that it is important to take into account these results that 
shows how even after being exposed to high levels of antibiotic, the remaining viable cells 
might be able to recover their osteogenic potential and  proliferate. Rathbone et al studies 
revealed that very high concentrations of vancomycin (2000 µg/mL) were not enough to 
inhibit human osteoblasts cells normal activity.(101)  
Regarding cell morphology, only preliminary assays were performed. Few or no cells 
attached to the material were observed by SEM and CLSM. This is probably a consequence 
of wrong preparation of the samples for microscopy observation. 
  
Concluding Remarks and Future work 
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Chapter 5: Concluding Remarks and Future work 
5.1.  Concluding remarks 
In this study, a nanoHA/collagen composite was used as a Drug Delivery System for 
vancomycin and the effects of this antibiotic on bone cells behavior were evaluated.  
Regarding the vancomycin release profile from heparinized nanoHA/collagen granules, it was 
observed that replacing 20 % of the PBS every 24 hours or replacing all the PBS three times 
a week did not affect vancomycin release profile, whose pattern was preserved. 
This study has also shown that heparinized nanoHA/collagen granules are a suitable carrier 
for controlled release of vancomycin once that they were able to release antibiotic in a 
sustainable way and in enough amounts to inhibit S. aureus growth at least for 192 hours. 
In fact, heparinized nanoHA/collagen granules were successfully used as drug carrier for a 
controlled release of vancomycin. This antibiotic seems to reveal a cytostatic effect on both 
osteoblasts and osteoclasts differentiation. Both cultures showed a substantial decrease of 
cells’ metabolic activity and differentiation over time when in contact with vancomycin. 
NanoHA/collagen and heparinized nanoHA/collagen granules showed better properties for 
cell adhesion, proliferation and differentiation. 
In osteoclasts culture, the change of medium did not seem to interfere with those cells’ 
differentiation since significant changes in TRAP activity were not observed. But cells showed 
a significantly better behavior in terms of differentiation when in contact with heparinized 
nanoHA/collagen granules if culture medium was changed three times a week.  
Concerning MG63 osteoblast-like cells culture, metabolic activity did not decrease in the 
initial 14 and 21 days after culture and, at this point, it was expected that cells would be able 
to recover their function and proliferate. Probably the 200 mg/L ratio used was not the ideal 
for cell growth. 
As a conclusion, the heparinized nanoHA/collagen material proved to have a great potential 
to be used as DDS in clinical applications, namely in osteomyelitis treatment. The 
nanoHA/collagen granules used in this study have adequate dimensions, strength and 
macroporosity to be applied in those cases as they were designed to promote 
osseointegration and osteoconductivity. Although the cell cultures did not present the ideal 
conditions, bone cells were capable to adhere and proliferate on the material without 
vancomycin. 
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5.2.  Future work 
Concerning the MG63 osteoblast-like cells culture using a 100 mg/L ratio, the assay must be 
repeated in order to validate the preliminary results obtained. Therefore, further 
investigation are planned in order to establish the perfect culture conditions, namely 
concerning the amount of granules, as well as the techniques used in the experiment. 
A co-culture system with osteoblasts and osteoclasts should be tried in order simulate a 
more likely bone environment and, therefore, assess the influence of the heparinized 
nanoHA/collagen material and vancomycin. Moreover, vancomycin release profile from the 
heparinized nanoHA/collagen granules must be tested in the infection environment once the 
conditions presented are quite different and may influence vancomycin’s release. 
In vivo studies on osteomyelitis rat models are already being performed to assess the 
possible effectiveness of this biomaterial in the treatment of osteomyelitis. It would be also 
interesting to explore vancomycin’s bioactivity in other bacteria such as Staphylococcus 
epidermidis and MRSA and in VRSA, once that the occurrence of vancomycin resistant 
strains has been reported.  
Additionally, fluorescence polarization immunoassay, which is commonly used in clinical 
practice, should be tried in order to assess vancomycin concentration directly from the 
patients’ serum. 
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